New drug combo aims to shrink advanced cervical cancer

NCT ID NCT06238635

Ongoing Disease control Sponsor: Meghan Shea Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether combining two immunotherapy drugs, dostarlimab and cobolimab, can shrink tumors or slow the growth of advanced cervical cancer that has spread or returned. About 66 participants with measurable disease will receive the drugs by IV. The main goal is to see how many people respond, with secondary goals including how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dostarlimab and cobolimab (two immunotherapy drugs given by IV)
What this could lead to: If it works, this combination could offer a new treatment option for people with advanced cervical cancer that has spread or come back.
What could go wrong: This is a small, early-phase trial (66 people) with no control group, so results may not apply broadly. Immunotherapy can cause immune-related side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CERVICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CERVICAL CARCINOMA CERVICAL CANCER METASTATIC CERVICAL CANCER METASTATIC CERVICAL CARCINOMA RECURRENT CERVICAL CARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.